Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Phase II Trial of Preoperative Chemotherapy With Gemcitabine/ Cisplatin /S-1 (GCS) for Biliary Tract Cancers With Lymph Node Metastasis Diagnosed by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)

Trial Profile

A Multicenter Phase II Trial of Preoperative Chemotherapy With Gemcitabine/ Cisplatin /S-1 (GCS) for Biliary Tract Cancers With Lymph Node Metastasis Diagnosed by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Feb 2019

At a glance

  • Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary)
  • Indications Biliary cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Feb 2019 Status changed from recruiting to active, no longer recruiting.
    • 31 Aug 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Feb 2017.
    • 28 Mar 2013 Planned end date changed to 1 Feb 2019 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top